InnoCare Pharma Limited
InnoCare Pharma Limited is a clinical- and commercial-stage biopharmaceutical company that discovers, develops and commercialises drugs for the treatment of cancer and autoimmune diseases. Its research and operating sites are located in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States. The company was founded in 2015 by Dr Jisong Cui, who serves as Chairman and Chief Executive Officer, together with structural biologist Academician Yigong Shi.
Although the on-file registry record for this profile shows a Chinese operating base, InnoCare Pharma Limited itself is incorporated in the Cayman Islands, consistent with the holding-company structure used by most dual Hong Kong / mainland-listed Chinese biopharmaceutical groups; its principal operations are carried out through Chinese subsidiaries based in Beijing.
InnoCare Pharma Limited is dual-listed. Its H-shares have traded on the Main Board of the Hong Kong Stock Exchange under stock code 9969 since its IPO in 2020, and its A-shares have traded on the Shanghai Stock Exchange’s Science and Technology Innovation Board (STAR Market) under code 688428 since 2021. Stock code 1801.HK belongs to a different, unrelated company, Innovent Biologics, Inc., and should not be confused with InnoCare Pharma Limited.
The company has three approved, marketed products. Orelabrutinib, a BTK inhibitor marketed in China as Yinuokai, is approved for relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), and as a first-line CLL/SLL treatment in China; it is also approved in Singapore and Australia and is included in China’s national reimbursement drug list. Tafasitamab, a CD19-targeted monoclonal antibody marketed as Mingnuokai, is approved in China in combination with lenalidomide for relapsed/refractory diffuse large B-cell lymphoma. Zurletrectinib, a pan-TRK inhibitor marketed as Yinuoxin, is approved in China for NTRK fusion-positive solid tumours in adults and adolescents. The pipeline also includes additional candidates in oncology and immunology.
On-file registry status for InnoCare Pharma Limited is Active. No independently verified group revenue or employee figures are cited here; company-level financial results are reported in InnoCare’s periodic filings with the Hong Kong Stock Exchange and the Shanghai Stock Exchange.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of InnoCare Pharma Limited
The on-file registry data for InnoCare Pharma Limited lists ten disclosed shareholding records, of which five are shown in this profile: DFA Emerging Markets Small Cap Series (1.12%), SPDR S&P China ETF (0.28%), iShares Core MSCI Emerging Markets ETF (12.78%), Vanguard International Stock Index Fund – Emerging Markets Stock Index (13.87%) and Vanguard International Equity Index Funds – FTSE All-World ex-US Small-Cap Index (4.04%), each verified as of 2 August 2026 and denominated in Hong Kong dollars. These are passive institutional/index-fund holdings, consistent with Hong Kong Stock Exchange substantial-shareholder disclosure notices triggered above the statutory notifiable threshold, rather than a complete shareholder register. InnoCare Pharma Limited is a widely held, dual-listed public company, and the majority of its shares are held by retail and other institutional investors not captured in this snapshot.
Founder and Chairman/CEO Dr Jisong Cui’s personal shareholding was not independently verified in this research session. His interest, together with that of co-founder Academician Yigong Shi and any early venture investors, would be disclosed in InnoCare’s Hong Kong Stock Exchange substantial-shareholder filings and annual report, but was not located from the sources reviewed here.
Data availability
Hong Kong Stock Exchange rules require disclosure only of shareholders whose interest crosses the notifiable threshold (broadly 5%, with lower disclosure thresholds applying to some fund managers), so the available shareholder data for InnoCare Pharma Limited is best classified as Major shareholders only; it does not represent a full shareholder register.
Sources
Zavia.ai registry data (shareholder disclosure snapshot, verified 2 August 2026). InnoCare Pharma Limited investor relations, innocarepharma.com/investor/stock, retrieved 15 September 2026.
Registry feed — rows exactly as filed with SAMR — public search via GSXT (National Enterprise Credit Information Publicity System), including entries the profile above does not cover.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Vanguard International Stock Index-Emerging Markets Stk | 13.9% | SAMR — public search via GSXT (National Enterprise Credit Information Publicity System) | |
| iShares, Inc.-iShares Core MSCI Emerging Markets ETF | 12.8% | SAMR — public search via GSXT (National Enterprise Credit Information Publicity System) | |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 4% | SAMR — public search via GSXT (National Enterprise Credit Information Publicity System) | |
| DFA Emerging Markets Small Cap Series | 1.1% | SAMR — public search via GSXT (National Enterprise Credit Information Publicity System) | |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) China ETF | 0.3% | SAMR — public search via GSXT (National Enterprise Credit Information Publicity System) |
Officers
11
Directors and officers of InnoCare Pharma Limited
The on-file registry data lists 11 officer records for InnoCare Pharma Limited, of which five are shown in this profile, all flagged active with no resignation dates recorded: Nan Gao (Chief Operating Officer), Xiangyang Chen, Ph.D. (Chief Technology Officer), Junjian Liu, Ph.D. (Senior Vice President of Biology and Biologics), Yue Tan (Accounting Supervisor) and Junsu Wang (General Counsel). InnoCare’s own investor-relations pages additionally identify Dr Jisong Cui as Co-founder, Chairman and Chief Executive Officer, Xin Fu as Chief Financial Officer, Shaofeng Chen as Chief Business Officer and Qiang Zhou, Ph.D. as Chief Medical Officer, none of whom appear in the on-file officer sample.
The board of directors, per the company’s corporate governance disclosures, comprises Dr Jisong Cui (Chairman), Ronggang Xie (Non-Executive Director), Lan Hu (Independent Non-Executive Director; Chair of the Audit Committee and Chair of the Compensation Committee), Dandan Dong, Ph.D. (Independent Non-Executive Director) and Prof. Kunliang Guan (Independent Non-Executive Director). Nationality is not disclosed for any of these individuals in the sources reviewed and has not been inferred from name, residence or address. No resignation or removal dates were identified for any current officer or director in this research session.
Recent officer changes
No verified recent appointment, resignation or role-change activity was identified from the sources reviewed in this research session.
Data availability
Officer and director information for a Hong Kong / Shanghai dual-listed company of this kind is disclosed through corporate governance reports, annual reports and exchange announcements rather than a single company-registry officer filing. The available information should be treated as Partial, reflecting the roles the company has chosen to publish rather than a complete historical officer record.
Sources
Zavia.ai registry data (officer snapshot, last synced 11 August 2026). InnoCare Pharma Limited corporate website, innocarepharma.com/about/team and innocarepharma.com/investor/governance, retrieved 15 September 2026.
Registry feed — rows exactly as filed with SAMR — public search via GSXT (National Enterprise Credit Information Publicity System), including entries the profile above does not cover.
Group Structure
Group structure of InnoCare Pharma Limited
InnoCare Pharma Limited is the top-level, publicly traded holding company of its group; no parent or controlling company was identified for this entity. The on-file registry data records no verified parent, subsidiary or ownership linkage for InnoCare Pharma Limited, noting only that no branch or international-presence data is available from the source registry. InnoCare’s own disclosures indicate that the group operates through Chinese operating subsidiaries and research sites in Beijing, Nanjing, Shanghai and Guangzhou, together with a Hong Kong entity and a US-based subsidiary supporting international clinical and business-development activities, but this research session could not independently verify the specific legal names, registration numbers or ownership percentages of those subsidiaries from a primary filing, so they are not listed individually here.
Data availability
Group-structure information for InnoCare Pharma Limited is best classified as Not found for this profile: the on-file registry carries no linkage data, and while the company’s own annual report is likely to disclose a full list of subsidiaries, that document could not be reviewed in machine-readable form during this research session.
Sources
Zavia.ai registry data (group-linkage snapshot). InnoCare Pharma Limited annual report filings referenced at innocarepharma.com/investor/finance, retrieved 15 September 2026 (PDF text not extracted in this session).
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does InnoCare Pharma Limited do?
InnoCare Pharma Limited is a clinical- and commercial-stage biopharmaceutical company that discovers, develops and commercialises drugs for cancer and autoimmune diseases, with research and operating sites in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.
What is InnoCare Pharma Limited's stock ticker and where is it listed?
InnoCare Pharma Limited is dual-listed: its H-shares trade on the Main Board of the Hong Kong Stock Exchange under code 9969 (listed since 2020), and its A-shares trade on the Shanghai Stock Exchange STAR Market under code 688428 (listed since 2021).
Is InnoCare Pharma Limited the same company as the one trading as 1801.HK?
No. Stock code 1801.HK on the Hong Kong Stock Exchange belongs to Innovent Biologics, Inc., a separate and unrelated biopharmaceutical company. InnoCare Pharma Limited trades under Hong Kong stock code 9969.
Where is InnoCare Pharma Limited incorporated?
InnoCare Pharma Limited is incorporated in the Cayman Islands. The "China" jurisdiction shown on file for this profile reflects the company's principal Chinese operating base in Beijing rather than its place of incorporation, a structure common to Hong Kong / mainland dual-listed Chinese biopharmaceutical groups.
When was InnoCare Pharma founded and by whom?
InnoCare Pharma was founded in 2015 by Dr Jisong Cui and Academician Yigong Shi, a structural biologist. Dr Cui serves as the company's Chairman and Chief Executive Officer.
What are InnoCare Pharma Limited's approved, marketed drugs?
The company markets three approved products: orelabrutinib (Yinuokai), a BTK inhibitor for CLL/SLL, MCL and MZL; tafasitamab (Mingnuokai), a CD19-targeted monoclonal antibody for relapsed/refractory diffuse large B-cell lymphoma; and zurletrectinib (Yinuoxin), a pan-TRK inhibitor for NTRK fusion-positive solid tumours.
Who is the Chairman and CEO of InnoCare Pharma Limited?
Dr Jisong Cui is Co-founder, Chairman and Chief Executive Officer of InnoCare Pharma Limited, per the company's own investor relations disclosures.
Who are InnoCare Pharma Limited's major shareholders?
Disclosed substantial shareholders include passive institutional/index funds such as iShares Core MSCI Emerging Markets ETF (12.78%) and the Vanguard International Stock Index Fund – Emerging Markets Stock Index (13.87%), as verified 2 August 2026. This reflects Hong Kong Stock Exchange notifiable-interest disclosures rather than a complete shareholder register; the founders' personal shareholdings were not independently verified in this research session.
Does InnoCare Pharma Limited have a disclosed Ultimate Beneficial Owner (UBO)?
No verified UBO was identified for InnoCare Pharma Limited in this research session. As a widely held, dual-listed public company, its ownership is dispersed among institutional and retail shareholders rather than concentrated in a single beneficial owner meeting a typical UBO threshold.
What is InnoCare Pharma Limited's current registration status?
The on-file registry status for InnoCare Pharma Limited is Active.
Where is InnoCare Pharma Limited headquartered?
InnoCare Pharma's principal operating base is in Beijing, China, with additional research and business sites in Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.
Is InnoCare Pharma Limited part of a larger corporate group?
InnoCare Pharma Limited is itself the top-level, publicly traded holding company of its group. No parent or controlling company was identified, and specific subsidiary names and ownership percentages were not independently verified from a primary filing in this research session.
When did InnoCare Pharma list on the Hong Kong Stock Exchange and the Shanghai STAR Market?
InnoCare completed its Hong Kong Stock Exchange IPO in 2020 (stock code 9969) and subsequently listed its A-shares on the Shanghai Stock Exchange STAR Market in 2021 (stock code 688428), becoming a dual-listed H-share and A-share biopharmaceutical company.
Who chairs InnoCare Pharma Limited's board committees?
Per the company's corporate governance disclosures, Independent Non-Executive Director Lan Hu chairs both the Audit Committee and the Compensation Committee. Other board members include Dr Jisong Cui (Chairman), Ronggang Xie (Non-Executive Director), Dandan Dong, Ph.D. and Prof. Kunliang Guan (both Independent Non-Executive Directors).